Regulating Methadone in Correctional Facilities and Our National Data Challenge

Brendan Saloner, PhD

Johns Hopkins Bloomberg School of Public Health NASEM Methadone Workshop March 4, 2022

Email: bsaloner@jhu.edu Twitter: @BrendanSaloner

Disclosures

No conflicts of interest to disclose

 Funding: NIDA (K01DA042139), Greenwall Foundation, Arnold Ventures, Bloomberg Philanthropies

An Alternative Regulatory Model for Jails and Prisons

- Yesterday's presentation from Jodi Rich underscored the problems of current methadone regulations in jails and prisons
- We found widespread challenges complying with a patchwork of state and federal rules, which are inconsistently applied.
- Best option for new regulations, described in a forthcoming White Paper with Josh Rising and Sara Whaley:¹
 - Expand the current hospital regulations to cover people who are incarcerated.

¹Josh Rising, Brendan Saloner, Sara Whaley. White Paper: Access to Methadone in Correctional Facilities. Johns Hopkins School of Public Health. March 4, 2022 Draft. https://tinyurl.com/4j27458h

The Rationale for a Hospital-Style Regulation

- Hospitals are allowed to handle methadone as they do any other controlled substance, and to dispense it to inpatients with OUD who are receiving treatment for non-OUD related causes¹
 - Like hospitals, correctional facilities are institutional settings of care where patients need interim care
 - Like hospitals, correctional facilities are very secure and often stock and dispense controlled medications
 - Like hospitals, a critical task is to connect patients to continuing community care
- Jails in particular are short-stay facilities, where many existing regulations around care provision are not well-matched to available resources and acute needs of a population that churns rapidly

Our National Data Challenge

- Workshop presentations provide a great compilation of available service use data, but there are huge holes in our understanding of access and quality of care. Lots of basic questions cannot be answered nationally:
- How many people want access to methadone but cannot get it?
- What is the national average retention in methadone and how many new patients enter treatment every year?
- What are the typical patterns of dosing, take-home, counseling, and UDS experienced among patients?
- Alongside regulatory changes, we need to modernize data collection infrastructure

Elements of a Data Strategy

- Modernize NSDUH to include incarcerated people and people experiencing homelessness
- Require methadone treatment to be identified in the Treatment Episode Data Set (instead of any MOUD)
- Undertake a national longitudinal cohort study of methadone patients to identify factors related to quality of care, recovery outcomes, and retention in treatment
- Plan for data collection activities outside the OTP to extend to mobile units, correctional facilities, long-term care, pharmacies

	Available Data	What we Don't Know
Size and Characteristics of Treated Population	 NSSATS: Point-in-time count (state aggregates) State admin data and claims: patient-level treatment records 	 National data that tracks patients longitudinally, national demographics of patients at OTPs
Access Barriers and Facilitators	 Select studies on travel distance, cost, and wait times 	 National, patient-centric measures on realized access and patient barriers
Quality of Care	 Select studies on retention, NSSATS facility measures on processes of care 	 National measures on whether care is effective, comprehensive, patient- centered
Medical Outcomes	 Small sample studies with patient-reports, claims-based analyses for specific payers 	 National trends in overdose risk among methadone patients, other self- reported markers of relapse/recovery
Non-Medical Outcomes	 Single state/county data linkage studies, small sample studies with patient reports 	 National trends in recidivism, child welfare involvement, employment, housing stability